Related Experiment Video
Updated: May 16, 2026
11:58
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Advancing Antibody-Drug Conjugates: Current Perspectives and Future Directions
Julian David Etessami1,2, Carmine Valenza1,2,3,4, Anthony W Tolcher5
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
Summary
Antibody-drug conjugates (ADCs) offer targeted cancer therapy with improved efficacy. Research explores combinations and next-generation platforms to overcome resistance and enhance patient outcomes in oncology.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) are a transformative class of cancer therapeutics.
- Advances in ADC technology have expanded their clinical use and efficacy across various malignancies.
- Challenges include tumor heterogeneity, resistance mechanisms, and on-target off-tumor toxicities.
Purpose of the Study:
- To review the current landscape of ADCs in oncology.
- To discuss strategies for overcoming resistance and managing toxicities.
- To highlight future directions in ADC development.
Main Methods:
- Review of clinical and translational research on ADCs.
- Analysis of combination and sequencing strategies.
- Examination of next-generation ADC platforms.
Main Results:
- ADCs demonstrate significant clinical benefit in numerous cancers.
- Combination therapies (e.g., with immunotherapy) show promise in enhancing antitumor activity.
- Next-generation ADCs aim to address heterogeneity and resistance.
Conclusions:
- ADCs are a cornerstone of modern cancer treatment, with ongoing advancements.
- Combination and sequencing strategies are crucial for optimizing ADC efficacy and managing toxicities.
- Future ADC platforms hold potential for improved patient outcomes.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:14Phase II Conjugation Reactions: Overview
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...